venBio Global Strategic Fund IV reports Attovia Therapeutics common share acquisition valued at $6.5 million - ATTO News | RalliesvenBio Global Strategic Fund IV reports Attovia Therapeutics common share acquisition valued at $6.5 million
A
ATTO• venBio Global Strategic Fund IV increases Attovia stake
- venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, reported a rise in its common stock stake to 4,181,367 shares.
- The increase included 382,352 shares bought at $17 per share.
- The filing also reflected additional shares received via conversions of preferred stock into common stock.
